|1.||Giovanella, Luca: 27 articles (08/2014 - 05/2002)|
|2.||Rivolta, Carina M: 20 articles (03/2015 - 08/2003)|
|3.||Targovnik, Héctor M: 19 articles (03/2015 - 08/2003)|
|4.||Tuttle, R Michael: 17 articles (12/2015 - 07/2002)|
|5.||Ceriani, Luca: 17 articles (02/2014 - 05/2002)|
|6.||Miyauchi, Akira: 13 articles (05/2014 - 07/2002)|
|7.||Schlumberger, Martin: 13 articles (08/2012 - 08/2002)|
|8.||Purisch, Saulo: 13 articles (06/2007 - 06/2004)|
|9.||Rose, Noel R: 12 articles (09/2011 - 04/2005)|
|10.||Braley-Mullen, Helen: 11 articles (11/2013 - 01/2005)|
|1.||Thyroid Neoplasms (Thyroid Cancer)
02/01/2014 - "Thyroglobulin (Tg), the most common marker to determine remission of differentiated thyroid carcinoma (DTC), can take 18 months or longer to be undetectable. "
09/01/2005 - "In addition presurgical serum thyroglobulin levels were not correlated with the disease outcome after a mean follow-up of 9 years: no difference was found among patients in complete remission or with persistent disease or dead from thyroid cancer. "
05/01/1978 - "Presently, it appears that reverse T3 and 3,3'T2 measurements in amniotic fluid and cord serum may potentially be useful in diagnosing fetal or neonatal thyroid dysfunction, and serum thyroglobulin measurements appear to be important as a measure of the efficacy of treatment of patients with differentiated thyroid carcinoma."
02/01/2014 - "(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) has proved effective in detecting recurrent or metastatic differentiated thyroid carcinoma (DTC) in the follow-up of operated DTC patients with high thyroglobulin (Tg) levels and negative findings on radioiodine whole-body scan. "
02/01/2001 - "Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin."
|2.||Neoplasm Metastasis (Metastasis)
11/01/2013 - "The primary endpoints were (i) the best response to initial therapy defined as either remission (stimulated thyroglobulin [Tg] <1 ng/mL, negative ultrasonography) or persistent disease (biochemical and/or structural), and (ii) clinical status at final follow-up defined as no evidence of disease (suppressed Tg <1 ng/mL, negative ultrasonography), biochemical persistent disease (suppressed Tg >1 ng/mL in the absence of structural disease), structural persistent disease (locoregional or distant metastases), or recurrence (biochemical or structural disease identified after a period of no evidence of disease). "
12/01/2009 - "The results of PEIT show significant reduction in nodal size or complete disappearance of the node in more than 70% of patients, with a decrease in serum thyroglobulin, except for patients with distant metastases. "
02/01/2014 - "Lack of vascular invasion (p=0.04), presence of surgically amenable recurrence/metastasis (p=0.0001), and suppressible on-therapy serum thyroglobulin levels at the time of recurrent/metastatic disease (p=0.01) were strong predictors of clinical remission and good prognosis on multivariate analysis. "
12/01/2013 - "An optimized cutoff value for washout thyroglobulin was 1.8 ng/mL. The sensitivity and negative predictive value in diagnosing metastasis improved significantly with a cutoff value of 1.8 ng/mL compared with a cutoff value of 10 ng/mL (P = .0412 for sensitivity, P = .0188 for negative predictive value). "
04/01/2007 - "Five (5) months later, the 131I-WBS revealed the disappearance of RIU in some metastases and its significant reduction in other lesions, with a parallel drop in serum thyroglobulin. "
07/01/2013 - "Of 229 patients evaluable for outcome, 147 (64.2%) attained complete remission [negative iodine-131 whole-body scan and TSH-stimulated serum thyroglobulin (Tg) < 1 μg /L], 69 (30.1%) showed nearly complete remission (complete response, except stimulated Tg 1-10 μg/L), and 11 (4.8%) had partial remission (Tg > 10 μg/L, decrease from baseline in radioiodine uptake intensity in ≥ 1 focus, in tumor volume or in Tg). "
07/01/2002 - "Several methods for the detection of the tumor marker thyroglobulin (Tg) have been employed in 36 patients in apparent remission at the moment of the study. "
08/01/2010 - "Following thyroid surgery, an initial risk assessment of recurrence and disease-specific mortality is made using important intra-operative findings, histologic characteristics of the tumor, molecular profile of the tumor, post-operative serum thyroglobulin and any available cross-sectional imaging studies. "
09/01/2009 - "The aim of the study was to evaluate the use of Ab-Tg as tumor marker as a replacement for thyroglobulin (Tg). "
11/01/2008 - "To address these important limitations, this study used peptide immunoaffinity enrichment in concert with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify thyroglobulin, a well-characterized tumor marker. "
01/01/2003 - "However, there is overwhelming evidence to suggest that this approach is not fail-safe due to increasing reports of false negative and false positive results, which may result in missed or unwarranted therapy with (131)I. This article will review the current management of differentiated carcinoma of the thyroid and the possible causes of the reported inadequacy of thyroglobulin and (131)I whole-body scan to detect residual or recurrent disease, and the increasing role of alternative imaging, particularly (18)F-FDG PET in the management of this curable malignancy."
10/01/2002 - "A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas."
07/01/1999 - "Our recent study demonstrates the feasibility of the thyroglobulin (TG) promoter in transcriptionally targeted gene therapy for thyroid carcinomas expressing TG, albeit less effectively than the constitutive viral promoter. "
01/01/1999 - "Therefore, whole-body PET-FDG is a complementary diagnostic technique for study patients with CDT (Thyroid Differentiated Carcinoma) with 131I scan negative and rising thyroglobulin levels."
01/01/1983 - "Thyroglobulin in carcinoma of the thyroid: an immunohistochemical study."
10/01/2008 - "The serum thyroglobulin (Tg) measurement during hypothyroidism (offT4-Tg), just before radioiodine thyroid ablation, has proved to be effective for predicting persistent/recurrent disease. "
02/01/2006 - "Recently, the thyroglobulin (Tg) value measured during hypothyroidism just before 131I therapy (preablation Tg) has proved to be effective for predicting persistent/recurrent disease. "
06/01/2012 - "None of the women in this analysis had overt hypothyroidism, but mild hypothyroidism was evident in 27%; thyroglobulin antibody (TgAb) was ≥ 40 U/ml in 28% of the women. "
10/01/2011 - "HT is characterized by hypothyroidism that results from the destruction of the thyroid by thyroglobulin-specific T cell-mediated autoimmune response. "
07/29/2011 - "Mutations causing hypothyroidism might induce solely local/regional misfolding or may interfere more globally by impeding interactions between regions that are required for thyroglobulin secretion."
|4.||Thyrotropin (Thyroid-Stimulating Hormone)
|6.||Messenger RNA (mRNA)
|7.||Iodide Peroxidase (Deiodinase)
|9.||Calcitonin (Calcitonin, Eel)
|2.||Low-Level Laser Therapy (LLLT)
|3.||Neck Dissection (Radical Neck Dissection)
|5.||Drug Therapy (Chemotherapy)